248 related articles for article (PubMed ID: 25689143)
21. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Gomez-Panzani E; Ruszniewski P;
Endocr Relat Cancer; 2016 Mar; 23(3):191-9. PubMed ID: 26743120
[TBL] [Abstract][Full Text] [Related]
22. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors.
Janson ET
J Endocrinol Invest; 2005; 28(11 Suppl International):137-40. PubMed ID: 16625863
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy of somatostatin analogues in the treatment of neuroendocrine tumours based on the results of recent clinical trials].
Igaz P
Orv Hetil; 2014 Nov; 155(48):1908-12. PubMed ID: 25417137
[TBL] [Abstract][Full Text] [Related]
24. Hypoglycemia induced by long-acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor.
Unek IT; Celtik A; Yener S; Yavuzsen T; Alacacioglu A; Cokmert S; Oztop I; Demirkan B; Dicle O; Sagol O; Bekis R; Yilmaz U
J BUON; 2009; 14(1):135-8. PubMed ID: 19365885
[TBL] [Abstract][Full Text] [Related]
25. Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity With Lanreotide Autogel/Depot (LAN) Versus Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data.
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):6-7. PubMed ID: 27168103
[No Abstract] [Full Text] [Related]
26. Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system.
Faiss S; Scherübl H; Riecken EO; Wiedenmann B
Recent Results Cancer Res; 1996; 142():193-207. PubMed ID: 8893342
[TBL] [Abstract][Full Text] [Related]
27. [Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors].
Simonenko VB; Dulin PA; Makanin MA
Klin Med (Mosk); 2006; 84(4):4-8. PubMed ID: 16755846
[TBL] [Abstract][Full Text] [Related]
28. Multiple effects of somatostatin analogs verified in three cases of metastasized neuroendocrine tumors of the gastroenteropancreatic system.
Biliotti G; Martini F; Vaggelli L; Messerini L; Colagrande S; Pupi A; Seghi P
Tumori; 2006; 92(2):170-4. PubMed ID: 16724698
[TBL] [Abstract][Full Text] [Related]
29. The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.
Verslype C; Carton S; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Hootegem P; Van Laethem JL; Van Cutsem E
Acta Gastroenterol Belg; 2009; 72(1):54-8. PubMed ID: 19402373
[TBL] [Abstract][Full Text] [Related]
30. Hormone and Receptor Candidates for Target and Biotherapy of Neuroendocrine Tumors.
Hofland LJ; Vandamme T; Albertelli M; Ferone D
Front Horm Res; 2015; 44():216-38. PubMed ID: 26303715
[TBL] [Abstract][Full Text] [Related]
31. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors.
Faiss S; Räth U; Mansmann U; Caird D; Clemens N; Riecken EO; Wiedenmann B
Digestion; 1999; 60(5):469-76. PubMed ID: 10473972
[TBL] [Abstract][Full Text] [Related]
32. Antitumor effects of somatostatin analogs in neuroendocrine tumors.
Sidéris L; Dubé P; Rinke A
Oncologist; 2012; 17(6):747-55. PubMed ID: 22628056
[TBL] [Abstract][Full Text] [Related]
33. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.
Faggiano A
J Endocrinol Invest; 2024 Jan; 47(1):35-46. PubMed ID: 37581846
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?
Merola E; Alonso Gordoa T; Zhang P; Al-Toubah T; Pellè E; Kolasińska-Ćwikła A; Zandee W; Laskaratos F; de Mestier L; Lamarca A; Hernando J; Cwikla J; Strosberg J; de Herder W; Caplin M; Cives M; van Leeuwaarde R
Oncologist; 2021 Apr; 26(4):294-301. PubMed ID: 33301235
[TBL] [Abstract][Full Text] [Related]
35. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
[TBL] [Abstract][Full Text] [Related]
36. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Rinke A; Müller HH; Schade-Brittinger C; Klose KJ; Barth P; Wied M; Mayer C; Aminossadati B; Pape UF; Bläker M; Harder J; Arnold C; Gress T; Arnold R;
J Clin Oncol; 2009 Oct; 27(28):4656-63. PubMed ID: 19704057
[TBL] [Abstract][Full Text] [Related]
37. The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas GA; Besser GM; Grossman AB
Endocr Rev; 2004 Jun; 25(3):458-511. PubMed ID: 15180952
[TBL] [Abstract][Full Text] [Related]
38. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.
Klink AJ; Feinberg B; Yu HT; Ray D; Pulgar S; Phan A; Vinik A
Oncologist; 2019 Oct; 24(10):1331-1339. PubMed ID: 31015313
[TBL] [Abstract][Full Text] [Related]
39. [Recent advances in treatment of pancreatic neuroendocrine tumors].
Imamura M
Nihon Geka Gakkai Zasshi; 2008 May; 109(3):143-6. PubMed ID: 18536317
[TBL] [Abstract][Full Text] [Related]
40. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
Faggiano A; Tavares LB; Tauchmanova L; Milone F; Mansueto G; Ramundo V; De Caro ML; Lombardi G; De Rosa G; Colao A
Clin Endocrinol (Oxf); 2008 Nov; 69(5):756-62. PubMed ID: 18485119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
